{
  "abstract": "Aims\n\nTo describe treatment patterns and outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with embolization.Materials & methods\n\nThis retrospective observational study used Optum's de-identified Market Clarity Data. US adults with HCC treated with embolization between July 2016-September 2022 were followed from first embolization following diagnosis until death and end of enrollment or study period.Results\n\nOf 1,458 patients, 41.9%, 33.5%, and 24.6% received transarterial radioembolization (TARE), transarterial chemoembolization (TACE), and transarterial embolization (TAE), respectively, as initial embolization therapy; TARE use increased over time. Most were male (74.6%), white (66.5%), with a median age at index of 65.0 years, and 63.1% required ≥1 subsequent treatment (median treatment pattern follow-up: 16.3 months). Median (95% CI) time to first follow-up treatment or death was 5.9 (5.5-6.4) months. Compared with TARE, risk of death was lower with TACE (HR [95% CI] 0.82 [0.69-0.97]; P = 0.0242], non-significant in missingness sensitivity analysis) and higher with TAE (HR [95% CI] 1.25 [1.05-1.49]; P = 0.0135]).Conclusion\n\nTARE was the most common initial embolization therapy and its use increased over time. Time to first follow-up treatment or death was relatively short. Future studies are needed to identify optimal treatment approaches.",
  "abstract_shown": true,
  "affiliations": [
    "Division of Diagnostic, Molecular, and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.",
    "Oncology Outcomes Research, AstraZeneca, Mississauga, Ontario, Canada.",
    "Oncology Data and Analytics, AstraZeneca, Gaithersburg, Maryland, USA.",
    "Oncology Business Unit, US Medical Affairs, AstraZeneca, Gaithersburg, Maryland, USA.",
    "Oncology Biometrics, AstraZeneca, South San Francisco, California, USA.",
    "Oncology Outcomes Research, AstraZeneca, Cambridge, UK.",
    "Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA."
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 9,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Kirema Garcia-Reyes",
      "orcid": "0000-0002-9877-1334"
    },
    {
      "affs": [
        1
      ],
      "name": "William H Wang",
      "orcid": "0009-0000-6033-7041"
    },
    {
      "affs": [
        1
      ],
      "name": "Mufiza Farid-Kapadia",
      "orcid": "0000-0001-8242-2343"
    },
    {
      "affs": [
        2
      ],
      "name": "Nehemiah Kebede",
      "orcid": "0000-0001-9704-9641"
    },
    {
      "affs": [
        3
      ],
      "name": "Dex L Underwood",
      "orcid": "0009-0008-4066-7594"
    },
    {
      "affs": [
        4
      ],
      "name": "Ling Cai"
    },
    {
      "affs": [
        5
      ],
      "name": "Heide A Stirnadel-Farrant",
      "orcid": "0000-0003-0734-0422"
    },
    {
      "affs": [
        3
      ],
      "name": "Cindy Wang"
    },
    {
      "affs": [
        6
      ],
      "name": "Neehar D Parikh",
      "orcid": "0000-0002-5874-9933"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/68z43ewab562t.bib",
  "cited_by": 0,
  "doi": "10.1080/20450923.2026.2736861",
  "fulltext_url": "https://europepmc.org/articles/PMC13685556",
  "id": "68z43ewab562t",
  "issns": [
    "2045-0923",
    "2045-0931"
  ],
  "landing_url": "https://europepmc.org/article/MED/42895274",
  "language": "eng",
  "licence": "CC-BY-NC",
  "licence_label": "CC BY-NC",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "openalex",
      "2721|Hepatocellular Carcinoma Treatment and Prognosis"
    ]
  ],
  "openalex": "W7222931300",
  "pdf_url": "https://europepmc.org/articles/PMC13685556?pdf=render",
  "pmcid": "PMC13685556",
  "pmid": "42895274",
  "published": "2026-10-19",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/68z43ewab562t.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:19:33Z",
      "native_id": "MED:42895274",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42895274"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2721|Hepatocellular Carcinoma Treatment and Prognosis",
      "subfield": "general"
    }
  ],
  "title": "Treatment patterns and outcomes in US patients with unresectable HCC treated with embolization.",
  "title_text": "Treatment patterns and outcomes in US patients with unresectable HCC treated with embolization.",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:19:33Z",
  "url": "https://research.draconitic.com/paper/68z43ewab562t",
  "venue": "Hepatic oncology",
  "versions": []
}